Search for a command to run...
(Kommissionens forordning (EU) 2015/1221 af 24. juli 2015 om ændring af forordning (EF) nr. 1272/2008 om klassificering, mærkning og emballering af stoffer og blandinger med henblik på teknisk og videnskabelig tilpasning)
Bilag VI i forordning (EF) nr. 1272/2008 ændres som angivet i bilaget til nærværende forordning.
Uanset artikel 3, stk. 2, kan de harmoniserede klassificeringer, som er fastsat i bilaget til denne forordning, finde anvendelse før den i artikel 3, stk. 2, nævnte dato.
1. Denne forordning træder i kraft på tyvendedagen efter offentliggørelsen i Den Europæiske Unions Tidende.
2. Artikel 1 finder anvendelse for stoffer og blandinger fra den 1. januar 2017.
Denne forordning er bindende i alle enkeltheder og gælder umiddelbart i hver medlemsstat.
Udfærdiget i Bruxelles, den 24. juli 2015.
EUT L 353 af 31.12.2008, s. 1.
Rådets direktiv 67/548/EØF af 27. juni 1967 om tilnærmelse af lovgivning om klassificering, emballering og etikettering af farlige stoffer (EFT 196 af 16.8.1967, s. 1).
Europa-Parlamentets og Rådets forordning (EF) nr. 1907/2006 af 18. december 2006 om registrering, vurdering og godkendelse af samt begrænsninger for kemikalier (REACH), om oprettelse af et europæisk kemikalieagentur og om ændring af direktiv 1999/45/EF og ophævelse af Rådets forordning (EØF) nr. 793/93 og Kommissionens forordning (EF) nr. 1488/94 samt Rådets direktiv 76/769/EØF og Kommissionens direktiv 91/155/EØF, 93/67/EØF, 93/105/EF og 2000/21/EF (EUT L 396 af 30.12.2006, s. 1).
Bilag VI, del 3, til forordning (EF) nr. 1272/2008 ændres således:
1) I tabel 3.1 foretages følgende ændringer:
a) Angivelserne, der svarer til indeksnumrene 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, og 613-149-00-7, erstattes af følgende angivelser:
Indeksnr. International kemisk identifikation EF-nr. CAS-nr. Klassificering Mærkning Specifikke koncentrationsgrænser, M-faktorer Noter Fareklasse- og kategorikode(r) Faresætningskode(r) Piktogram-, signalordskode(r) Faresætningskode(r) Suppl. faresætningskode(r)
2) I tabel 3.2 foretages følgende ændringer:
a) Angivelserne, der svarer til indeksnumrene 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X og 613-149-00-7, erstattes af følgende angivelser:
Indeksnr. International kemisk identifikation EF-nr. CAS-nr. Klassificering Mærkning Koncentrationsgrænser Noter 007-004-00-1 salpetersyre … % 231-714-2 7697-37-2 O; R8 C; R35 O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63 O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 % B 015-003-00-2 calciumphosphid; tricalciumdiphosphid 215-142-0
| 007-004-00-1 | salpetersyre … % | 231-714-2 | 7697-37-2 | Ox. Liq. 2 Skin Corr. 1A | H272 H314 | GHS03 GHS05 Dgr | H272 H314 | EUH071 | Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % | B |
| 015-003-00-2 | calciumphosphid; tricalciumdiphosphid | 215-142-0 | 1305-99-3 | Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 | H260 H300 H311 H330 H318 H400 | GHS02 GHS06 GHS05 GHS09 Dgr | H260 H300 H311 H330 H318 H400 | EUH029 EUH032 | M = 100 |
| 031-001-00-4 | galliumarsenid | 215-114-8 | 1303-00-0 | Repr. 1B Carc. 1B STOT RE 1 | H360F H350 H372 (åndedrætssystemet og det hæmatopoietiske system) | GHS08 Dgr | H360F H350 H372 (åndedrætssystemet og det hæmatopoietiske system) |
| 050-008-00-3 | tributyltinforbindelser, undtagen sådanne nævnt andetsteds i dette bilag | — | — | Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H301 H312 H372** H315 H319 H400 H410 | GHS08 GHS06 GHS09 Dgr | H360FD H301 H312 H372** H315 H319 H410 | * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 | A 1 |
| 603-102-00-9 | 1,2-epoxybutan | 203-438-2 | 106-88-7 | Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 | H225 H351 H302 H312 H332 H335 H315 H319 | GHS02 GHS08 GHS07 Dgr | H225 H351 H302 H312 H332 H335 H315 H319 |
| 603-197-00-7 | tebuconazol (ISO); 1-(4-chlorphenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H302 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d*** H302 H410 | M = 1 M = 10 |
| 606-054-00-7 | isoxaflutol (ISO); 5-cyclopropyl-1,2-oxazol-4-yl- α,α,α-trifluor-2-mesyl-p-tolylketon | — | 141112-29-0 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H400 H410 | GHS08 GHS09 Wng | H361d*** H410 | M = 10 M = 100 |
| 607-197-00-8 | nonansyre | 203-931-2 | 112-05-0 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Wng | H315 H319 H412 |
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorphenyl)ethyl]-1H-imidazol | 252-615-0 | 35554-44-0 | Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 | H351 H301 H332 H318 H410 | GHS08 GHS06 GHS05 GHS09 Dgr | H351 H301 H332 H318 H410 | M = 10 |
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholin | 216-474-9 | 1593-77-7 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (lever) H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H361d H373 (lever) H314 H317 H410 | EUH071 | M = 1 M = 1 |
| 613-133-00-X | etridiazol (ISO); 5-ethoxy-3-trichlormethyl-1,2,4-thiadiazol | 219-991-8 | 2593-15-9 | Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H317 H410 | M = 1 M = 1 |
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chlorpyridazin-3(2H)-on | 405-700-3 | 96489-71-3 | Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Dgr | H331 H301 H410 | M = 1 000 M = 1 000 |
b) Følgende angivelser indsættes i overensstemmelse med rækkefølgen i tabel 3.1:
| Indeksnr. | International kemisk identifikation | EF-nr. | CAS-nr. | Klassificering | Mærkning | Specifikke koncentrationsgrænser, M-faktorer | Noter | | | | | ------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------- | --------------------------------------------- | ------------------------------------------------------------------------------ | ------------------------------------------------ | -------------------------------------------- | ------------------------------------------- | ------ | ----------------- | | | Fareklasse- og kategorikode(r) | Faresætningskode(r) | Piktogram-, signalordskode(r) | Faresætningskode(r) | Suppl. faresætningskode(r) | | | | | | | | 019-003-00-3 | kalium-(E,E)-hexa-2,4-dienoat | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07 Wng | H319 | | | | | 604-092-00-9 | phenol, dodecyl-, forgrenet [1]; phenol, 2-dodecyl-, forgrenet; phenol, 3-dodecyl-, forgrenet; phenol, 4-dodecyl-, forgrenet; phenol, (tetrapropenyl)-, derivater [2] | 310-154-3 [1] | 121158-58-5 [1] 74499-35-7 [2] | Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | | M = 10 M = 10 | | | 606-148-00-8 | carvon (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [1] d-carvon (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [2] l-carvon; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [3] | 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] | 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07 Wng | H317 | | | | | 606-149-00-3 | tembotrion (ISO); 2-{2-chlor-4-(methylsulfonyl)-3-[(2,2,2-trifluorethoxy)methyl]benzoyl}cyclohexan-1,3-dion | — | 335104-84-2 | Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (øjne, nyrer og lever) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d H373 (øjne, nyrer og lever) H317 H410 | | M = 100 M = 10 | | | 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl-(2R)-2-{4-[(6-chlor-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoat | — | 71283-80-2 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 (nyrer) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 (nyrer) H317 H410 | | M = 1 M = 1 | | | 607-708-00-4 | octansyre | 204-677-5 | 124-07-2 | Skin Corr. 1C Aquatic Chronic 3 | H314 H412 | GHS05 Dgr | H314 H412 | | | | | 607-709-00-X | decansyre | 206-376-4 | 334-48-5 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Wng | H315 H319 H412 | | | | | 607-710-00-5 | 1,2-benzendicarboxylsyredipentylester, forgrenet og ligekædet | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | | | | | 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl-ethylcarbonat | — | 203313-25-1 | Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361fd H335 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361fd H335 H319 H317 H410 | | M = 1 M = 1 | | | 607-712-00-6 | dodemorphacetat; 4-cyclododecyl-2,6-dimethylmorpholin-4-iumacetat | 250-778-2 | 31717-87-0 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 | H361d H373 (lever) H314 H317 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H361d H373 (lever) H314 H317 H410 | EUH071 | M = 1 | | | 607-713-00-1 | fenpyroximat (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylen]amino}oxy)methyl]benzoat | — | 134098-61-6 | Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H330 H317 H400 H410 | GHS06 GHS09 Dgr | H301 H330 H317 H410 | | M = 100 M = 1 000 | | | 607-714-00-7 | triflusulfuron-methyl; methyl-2-({[4-(dimethylamino)-6-(2,2,2-trifluorethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoat | — | 126535-15-7 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | | M = 100 M = 10 | | | 607-715-00-2 | bifenazat (ISO); isopropyl-2-(4-methoxybiphenyl-3-yl)hydrazincarboxylat | 442-820-5 | 149877-41-8 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 H317 H410 | | M = 1 M = 1 | | | 613-319-00-0 | imidazol | 206-019-2 | 288-32-4 | Repr. 1B Acute Tox. 4 Skin Corr. 1C | H360D H302 H314 | GHS08 GHS07 GHS05 Dgr | H360D H302 H314 | | | | | 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidin-2,4(3H,5H)-dion | 218-499-0 | 2164-08-1 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | | M = 10 M = 10 | | | 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorphenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamid | — | 374726-62-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | | M = 1 M = 1 | | | 616-214-00-8 | metosulam (ISO); N-(2,6-dichlor-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-sulfonamid | — | 139528-85-1 | Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H373 (øjne og nyrer) H400 H410 | GHS08 GHS09 Wng | H351 H373 (øjne og nyrer) H410 | | M = 1 000 M = 100 | | | 616-215-00-3 | dimethenamid (ISO); 2-chlor-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamid | — | 163515-14-8 | Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Wng | H302 H317 H410 | | M = 10 M = 10 | | | 616-216-00-9 | flonicamid (ISO); N-(cyanmethyl)-4-(trifluormethyl)pyridin-3-carboxamid | — | 158062-67-0 | Acute Tox. 4 | H302 | GHS07 Wng | H302 | | | | | 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluormethyl)-3-pyridyl]ethyl}-λ6-sulfanyliden]cyanamid | — | 946578-00-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | | M = 1 M = 1 | |
| 1305-99-3 |
| F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50 |
| F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61 |
| N; R50: C ≥ 0,25 % |
| 031-001-00-4 | galliumarsenid | 215-114-8 | 1303-00-0 | Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23 | T R: 45-48/23-60 S: 45-53 | E |
| 050-008-00-3 | tributyltinforbindelser, undtagen sådanne nævnt andetsteds i dette bilag | — | — | Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53 | T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61 | T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | A 1 |
| 603-102-00-9 | 1,2-epoxybutan | 203-438-2 | 106-88-7 | F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38 | F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46 |
| 603-197-00-7 | tebuconazol (ISO); 1-(4-chlorphenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. Cat. 3; R63 Xn; R22 N; R50-53 | Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % |
| 606-054-00-7 | isoxaflutol (ISO); 5-cyclopropyl-1,2-oxazol-4-yl-α,α,α-trifluor-2-mesyl-p-tolylketon | — | 141112-29-0 | Repr. Cat. 3; R63 N; R50-53 | Xn; N R: 50/53-63 S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % |
| 607-197-00-8 | nonansyre | 203-931-2 | 112-05-0 | Xi; R36/38 N; R51-53 | Xi; N R: 36/38-51/53 S: (2-)46-61 |
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorphenyl)ethyl]-1H-imidazol | 252-615-0 | 35554-44-0 | Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53 | Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61 |
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholin | 216-474-9 | 1593-77-7 | Repr. Cat. 3; R63 C; R34 R43 N; R50-53 | C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61 | C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % |
| 613-133-00-X | etridiazol (ISO); 5-ethoxy-3-trichlormethyl-1,2,4-thiadiazol | 219-991-8 | 2593-15-9 | Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53 | Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % |
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chlorpyridazin-3(2H)-on | 405-700-3 | 96489-71-3 | T; R23/25 N; R50-53 | T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61 | N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 % |
b) Følgende angivelser indsættes i overensstemmelse med rækkefølgen i tabel 3.2:
Indeksnr. International kemisk identifikation EF-nr. CAS-nr. Klassificering Mærkning Koncentrationsgrænser Noter 019-003-00-3 kalium-(E,E)-hexa-2,4-dienoat 246-376-1 24634-61-5 Xi; R36 Xi R: 36 S: (2-)25-46 604-092-00-9 phenol, dodecyl-, forgrenet [1]; phenol, 2-dodecyl-, forgrenet; phenol, 3-dodecyl-, forgrenet; phenol, 4-dodecyl-, forgrenet; phenol, (tetrapropenyl)-, derivater [2] 310-154-3 [1]-[2] 121158-58-5 [1] 74499-35-7 [2] C; R34 N; R50-53 C; N R: 34-50/53- S: (1/2-)26-36/37/39-45-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 606-148-00-8 carvon (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [1] d-carvon (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [2] l-carvon; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [3] 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] R43 Xi R: 43 S: (2-)24-37 606-149-00-3 tembotrion (ISO); 2-{2-chlor-4-(methylsulfonyl)-3-[(2,2,2-trifluorethoxy)methyl]benzoyl}cyclohexan-1,3-dion 335104-84-2 Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl-(2R)-2-{4-[(6-chlor-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoat — 71283-80-2 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-708-00-4 octansyre 204-677-5 124-07-2 C; R34 N; R51-53 C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61 607-709-00-X decansyre 206-376-4 334-48-5 Xi; R36/38 N; R51-53 Xi; N R: 36/38-51/53 S: (2-)25-46-61 607-710-00-5 1,2-benzendicarboxylsyredipentylester, forgrenet og ligekædet 271-093-5 68515-50-4 Repr. Cat. 2; R60-61 T R: 60-61 S: 53-45 607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl-ethylcarbonat — 203313-25-1 Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53 Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61 Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-712-00-6 dodemorphacetat; 4-cyclododecyl-2,6-dimethylmorpholin-4-iumacetat 250-778-2 31717-87-0 Repr. Cat. 3; R63 C; R34 R43 N; R51-53 C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61 C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 % 607-713-00-1 fenpyroximat (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylen]amino}oxy)methyl]benzoat — 134098-61-6 T+; R26 Xn; R22 R43 N; R50-53 T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-714-00-7 triflusulfuron-methyl; methyl-2-({[4-(dimethylamino)-6-(2,2,2-trifluorethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoat — 126535-15-7 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-715-00-2 bifenazat (ISO); isopropyl-2-(4-methoxybiphenyl-3-yl)hydrazincarboxylat 442-820-5 149877-41-8 R43 N; R50-53 Xi; N R: 43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-319-00-0 imidazol 206-019-2 288-32-4 Repr. Cat 2; R61 Xn; R22 C; R34 T; C R: 22-34-61 S: 53-45 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidin-2,4(3H,5H)-dion 218-499-0 2164-08-1 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-213-00-2 mandipropamid (ISO); 2-(4-chlorphenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamid — 374726-62-2 N; R50-53 N R: 50/53 S: 60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 616-214-00-8 metosulam (ISO); N-(2,6-dichlor-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-sulfonamid — 139528-85-1 Carc. Cat. 3; R40 Xn; R48/22 N; R50-53 Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 % 616-215-00-3 dimethenamid (ISO); 2-chlor-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamid — 163515-14-8 Xn; R22 R43 N; R50-53 Xn; N R: 22-43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-216-00-9 flonicamid (ISO); N-(cyanmethyl)-4-(trifluormethyl)pyridin-3-carboxamid — 158062-67-0 Xn; R22 Xn R: 22 S: (2-)46 616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluormethyl)-3-pyridyl]ethyl}-λ6-sulfanyliden]cyanamid — 946578-00-3 Xn; R22 N; R50-53 Xn; N R: 22-50/53 S: (2-)60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
